Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Marc Yates
  • January 20, 2020
  • Articles

Happy Lunar New Year!

Happy Lunar New Year!

The Emerging Markets team at Research Partnership would like to wish you a happy and prosperous Lunar New Year.

2020 celebrates the Year of the Rat, an animal which represents vitality. It is also the first in the cycle of animals in Chinese Astrology, meaning 2020 is regarded as a year of improvements and new beginnings. 

read more »

  • Posted by Rachel Howard
  • January 16, 2020
  • Articles

Spotlight on Mexico: Healthcare under AMLO – One year on

Spotlight on Mexico: Healthcare under AMLO – One year on

Andrés Manuel López Obrador (commonly referred to by his initials AMLO) was elected President of Mexico in a landslide victory of December 2018. As we near the end of the first year of his six year term, we caught up with local expert Dr Xavier Tello, CEO of Strategic Consulting, to make sense of the latest changes in the healthcare system and consider what they mean for pharmaceutical manufacturers wishing to enter the Mexican market.“It has been a wild ride under AMLO”, Dr Tello told us. The changes have been rapid, complicated and unpredictable, and here we attempt to deconstruct the major events of the last 12 months.

read more »

  • Posted by Rachel Howard
  • December 18, 2019
  • Articles

How were the teenies? Reflecting on global healthcare and market research over the last decade

How were the teenies? Reflecting on global healthcare and market research over the last decade

Back in 2010, I presented my perspective on what the 2010s might look like for healthcare market research and business intelligence at the BHBIA Winter Seminar. As we round out the decade, I thought it would be timely to revisit my predictions and consider which of them actually came to fruition over the last decade, which did not, and why. My first reaction, looking back over my (already horrifyingly dated looking) PowerPoint slides, was to cringe at the nickname I’d assigned to the coming years – “the teenies”. Much like “the noughties” before them, that never caught on. Fortunately, from that point on, the rest of my predictions proved a little more prescient – “on the right track, but a little wide of the mark” is how one of my colleagues summarised them. 

read more »

  • Posted by Harrison Gaiger
  • November 25, 2019
  • Articles

“Alexa, process this data for me” 3 ways the AI evolution is redefining how we collect market insights

“Alexa, process this data for me” 3 ways the AI evolution is redefining how we collect market insights

In this article first published in PME magazine, Marketing Manager Harrison Gaiger outlines the three ways AI is redefining how we collect market insights.

Amazon’s digital voice assistant Alexa is much more than just a convenient tool for setting reminders, streaming music and controlling the lights in our homes. It is a very real application of Artificial Intelligence (AI), a technology that has fast become an integral part of our daily lives. With all of the hype surrounding the more attention-grabbing applications of AI such as self-driving cars and super human-like robots - which most commentators say will be commonplace soon, it can often be difficult to appreciate just how much AI affects what we’re doing right now. We have all become so accustomed to AI without even realising it e.g., the autocorrect function on our smartphones and the automatic tagging of friends in our Facebook photos are both powered by AI.

read more »

  • Posted by Pei Li Teh & Wan Ling Neo
  • November 15, 2019
  • Articles

Launching novel oncology therapies in Asia: Identifying and communicating value

Launching novel oncology therapies in Asia: Identifying and communicating value

Novel cancer therapies are offering patients new treatments and better outcomes worldwide. Recent changes in healthcare policies across APAC have reignited interest in the region as a strong market for oncology, such as China's fast tracking approval of therapies for severe and rare diseases and Vietnam's plan to cover health insurance for 80% of the population. Unfortunately, the often eye-watering costs of these new therapies means that, currently, for the many patients who still have to pay for treatment out of pocket, novel therapies are beyong reach. Pharma brands need to demonstate clear value if they want to achieve success. 

read more »